Mount Sinai Hospital

Running trials

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Not yet recruiting

  Isocaloric Navy-Bean Substitution in Adults With MASLD

  NCT07730853· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Atomoxetine in Melanocortin Obesity Syndrome

  NCT06899178· Phase 2· Icahn School of Medicine at Mount Sinai· Source

• Enrolling by invitation

  Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils

  NCT07639853· Medtronic Endovascular· Source

• Recruiting

  Tier Palliative Care For Patients With Advanced Heart Failure or Cancer

  NCT07391956· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Emory University· Source

• Active, not recruiting

  INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

  NCT07543367· Synchron, Inc.· Source

• Recruiting

  Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

  NCT07521475· Insulet Corporation· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  REPRESENT-PF Registry

  NCT07535268· Vivek Reddy· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· NRG Oncology· Source

• Recruiting

  Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

  NCT07285057· Phase 2· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Buntanetap in Participants With PD

  NCT07284784· Phase 2/3· Annovis Bio Inc.· Source

• Enrolling by invitation

  SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study

  NCT07116668· SafeHeal Inc· Source

• Recruiting

  A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

  NCT07187973· Phase 1· Disc Medicine, Inc· Source

• Recruiting

  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  NCT06686771· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

  NCT07143669· Blueprint Medicines Corporation· Source

• Enrolling by invitation

  Liver Transplant CGM

  NCT07216508· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment

  NCT07000045· Annapoorna Kini· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Not yet recruiting

  ExosomeDx in MRI-negative Men With High PSA

  NCT06966089· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  A Study of the MIND Diet for Persons With Multiple Sclerosis

  NCT06992115· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

  NCT06271590· Concept Medical Inc.· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

  NCT06976476· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  NCT06439836· Phase 1· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

  NCT06765356· Phase 4· Vivek Reddy· Source

• Recruiting

  Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

  NCT05519111· Phase 2· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Active, not recruiting

  NIOSH R21 WTC Asthma

  NCT07222501· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Medtronic Cardiovascular· Source

• Recruiting

  Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  NCT06632977· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Medical University of South Carolina· Source

• Recruiting

  Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

  NCT06228209· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  NCT06182397· Concept Medical Inc.· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Takeda· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

  NCT06699056· Peerbridge Health, Inc· Source

• Active, not recruiting

  Abbott Medical - VERITAS Study

  NCT06707688· Abbott Medical Devices· Source

• Recruiting

  The THOR IDE Study

  NCT05916950· Philips Clinical & Medical Affairs Global· Source

• Recruiting

  Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)

  NCT06575270· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

Showing 50 of 219.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers11 recruiting
• Prostate cancer8 recruiting
• Heart failure7 recruiting
• Lung cancer7 recruiting
• Stroke7 recruiting
• Colorectal cancer6 recruiting
• Coronary artery disease6 recruiting
• Ovarian cancer5 recruiting
• Atrial fibrillation4 recruiting
• Acute myeloid leukaemia3 recruiting
• Bladder cancer3 recruiting
• Endometrial cancer3 recruiting
• Kidney cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Multiple myeloma3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Peripheral artery disease3 recruiting
• Sarcoma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Aortic stenosis2 recruiting
• Brain aneurysm2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Crohn's disease2 recruiting
• Head and neck cancer2 recruiting
• HIV2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Multiple sclerosis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Sickle cell disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 2 diabetes2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Congenital heart disease1 recruiting
• Depression1 recruiting
• Dilated cardiomyopathy1 recruiting
• Fabry disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Frontotemporal dementia1 recruiting
• Gaucher disease1 recruiting
• Hearing loss1 recruiting
• Liver and biliary tract cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Postural tachycardia syndrome (POTS)1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Terminated

  Acute Migraine Treatment in the ED With Gepants

  NCT06985342· Phase 4· Icahn School of Medicine at Mount Sinai· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Immunovia, Inc.· Source

• Completed

  The PROTEMBO Trial

  NCT05873816· Protembis GmbH· Source

• Completed

  AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

  NCT06123130· HeartBeam, Inc.· Source

• Completed

  LS-PersAFone: Pulsed Field Ablation for Long-Standing Persistent Atrial Fibrillation

  NCT06128174· Vivek Reddy· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Recruiting

  A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

  NCT06083922· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Withdrawn

  mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT05918250· Phase 1· ModernaTX, Inc.· Source

• Completed

  Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

  NCT05510908· AIDS Malignancy Consortium· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Source

• Completed

  AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

  NCT05481359· Ablacon, Inc.· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

  NCT05019885· Phase 2· Madeline Fields· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Nuwellis, Inc.· Source

• Completed

  STEM-Parkinson's Disease

  NCT04797611· Scion NeuroStim· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

  NCT05231746· Phase 1· STCube, Inc.· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

• Completed

  AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

  NCT06378632· Cordio Medical· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Terminated

  The Effect of Structured Lifestyle Modification and Yoga Practice on Metabolic Processes Associated With Cardiovascular Disease

  NCT05250310· Icahn School of Medicine at Mount Sinai· Source

• Terminated

  SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

  NCT05010850· SafeHeal Inc· Source

• Completed

  Viz HCM (ECG Assist) Utilization Workflow Pilot

  NCT06600256· Viz.ai, Inc.· Source

• Withdrawn

  Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

  NCT04989283· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

  NCT05224869· Icahn School of Medicine at Mount Sinai· Source

• Terminated

  Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

  NCT04506086· Phase 4· Amgen· Source

• Completed

  Effect of Evolocumab on Coronary Plaque Characteristics

  NCT04710368· Phase 4· Annapoorna Kini· Source

• Completed

  Conduction System Pacing International Registry (CONSPIRE)

  NCT04831125· University of Chicago· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

  NCT04266197· Phase 2· Respira Therapeutics, Inc.· Source

• Completed

  Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

  NCT04182620· Vivek Reddy· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

  NCT04374877· Phase 1· Coherus Oncology, Inc.· Source

• Completed

  Human Epilepsy Project 3

  NCT05374928· NYU Langone Health· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Completed

  Real World and Genomic Data Based Asthma Insight Through Network Analysis

  NCT06623435· Icahn School of Medicine at Mount Sinai· Source

• Completed

  Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

  NCT04075526· Phase 1· NYU Langone Health· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

  NCT04284540· Icahn School of Medicine at Mount Sinai· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms

  NCT03642639· Cerenovus, Part of DePuy Synthes Products, Inc.· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Completed

  A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

  NCT03321630· Phase 2· NYU Langone Health· Source

• Completed

  Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

  NCT03275103· Phase 1· Genentech, Inc.· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 73.

Conditions

Diseases this institution publishes on or runs trials for.

• Aortic stenosis18 works · 7 trials
• Chronic lymphocytic leukaemia7 works · 3 trials